ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of LY3023414 in Japanese Participants With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02536586
Recruitment Status : Completed
First Posted : September 1, 2015
Last Update Posted : July 24, 2018
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The main purpose of this study is to evaluate the tolerability of an investigational drug known as LY3023414 in Japanese participants with advanced cancer or cancer that has spread to another part(s) of the body. The study will also explore the safety of the drug. It will measure how much of the drug gets into the blood steam and how long the body takes to get rid of it. It will investigate anti-cancer activity.

Condition or disease Intervention/treatment Phase
Neoplasm Drug: LY3023414 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of LY3023414 in Japanese Patients With Advanced Malignancies
Study Start Date : September 2015
Actual Primary Completion Date : February 9, 2017
Actual Study Completion Date : February 9, 2017

Arm Intervention/treatment
Experimental: LY3023414
LY3023414 administered orally, twice daily in 21-day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
Drug: LY3023414
LY3023414 administered orally.




Primary Outcome Measures :
  1. Number of Participants with LY3023414 Dose-Limiting Toxicities (DLT) [ Time Frame: Cycle 1 (21 days) ]

Secondary Outcome Measures :
  1. Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve (AUC) of LY3023414 [ Time Frame: Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.) ]
  2. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3023414 [ Time Frame: Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.) ]
  3. Proportion of Participants With Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR]) [ Time Frame: Baseline through study completion (estimated as up to five months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Have histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic and must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed or for whom standard therapy would not be appropriate.
  • Have the presence of measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • Have adequate organ and coagulation function.
  • Have discontinued all previous cancer therapies, and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 half-lives prior to study treatment, whichever is shorter, and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy for at least 42 days.
  • Are able to swallow capsules.
  • Males must agree to use medically approved barrier contraceptive precautions during the study and for 3 months following the last dose of study drug.
  • Females with childbearing potential: Must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug, must have had a negative serum or urine pregnancy test ≤7 days before the first dose of study drug.
  • A breastfeeding woman must not be breastfeeding. If a female who stops breastfeeding enters the study, breastfeeding must cease from the day of the first study drug administration until at least 3 months after the last administration.

Exclusion Criteria

  • Have serious pre-existing medical conditions.
  • Have symptomatic central nervous system malignancy or metastasis.
  • Have known acute or chronic leukemia or current hematologic malignancies that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
  • Have a known active fungal, bacterial, and/or known viral infection.
  • Intolerance to any previous treatment with any phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitor. Treatment with any PI3K/AKT/mTOR inhibitor must have discontinued for at least 21 days or 5 half-lives prior to first study drug administration, whichever is shorter, and participants must have recovered from the acute effects of therapy.
  • Have a second primary malignancy that, in the judgment of the investigator, and sponsor may affect the interpretation of results.
  • Participants with active alcohol abuse, as determined by the investigator.
  • Have a history of heart failure according to New York Heart Association Class ≥3.
  • Have corrected QT (QTc) interval of >470 milliseconds (msec) on screening electrocardiogram (ECG).
  • Have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus.
  • Have any evidence of clinically active interstitial lung disease (ILD).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02536586


Locations
Japan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Chiba, Japan, 277 8577
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Tokyo, Japan, 104-0045,
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT02536586     History of Changes
Other Study ID Numbers: 15838
I6A-JE-CBBH ( Other Identifier: Eli Lilly and Company )
First Posted: September 1, 2015    Key Record Dates
Last Update Posted: July 24, 2018
Last Verified: July 2018